Trial Profile

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Dec 2025 According to an Eli Lilly and Company media release, a formal progression-free survival (PFS) analysis to test for superiority is planned for a future analysis.
07 Dec 2025 According to an Eli Lilly and Company media release, data from the trial will be published in the Journal of Clinical Oncology and featured as part of the meeting's press program.
07 Dec 2025 According to an Eli Lilly and Company media release, progression-free survival data were immature but favored pirtobrutinib, showing a 43% reduction in the risk of disease progression or death in the ITT population; the treatment-naive subgroup, which had the longest follow-up, demonstrated a 76% risk reduction.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com